[go: up one dir, main page]

MX2018015583A - Metodos y composiciones para reducir el estres oxidativo. - Google Patents

Metodos y composiciones para reducir el estres oxidativo.

Info

Publication number
MX2018015583A
MX2018015583A MX2018015583A MX2018015583A MX2018015583A MX 2018015583 A MX2018015583 A MX 2018015583A MX 2018015583 A MX2018015583 A MX 2018015583A MX 2018015583 A MX2018015583 A MX 2018015583A MX 2018015583 A MX2018015583 A MX 2018015583A
Authority
MX
Mexico
Prior art keywords
oxidative stress
methods
compositions
reducing oxidative
reducing
Prior art date
Application number
MX2018015583A
Other languages
English (en)
Inventor
Kleidon William
Original Assignee
Ojai Energetics Pbc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ojai Energetics Pbc filed Critical Ojai Energetics Pbc
Publication of MX2018015583A publication Critical patent/MX2018015583A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

El estrés oxidativo se relaciona con varias condiciones de salud incluyendo, sin limitación, cáncer, envejecimiento, enfermedades neurodegenerativas y metabólicas. El aumento de niveles de estrés oxidativo puede resultar del aumento de exposición a la radiación u otros factores estresantes ambientales y/o disminución de efectos protectores de defensa celulares contra especies de oxígeno reactivo. La presente divulgación proporciona composiciones y métodos que comprenden compuestos cannabinoides encapsulados útiles para reducir el estrés oxidativo en un sujeto.
MX2018015583A 2016-06-15 2017-06-15 Metodos y composiciones para reducir el estres oxidativo. MX2018015583A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662350702P 2016-06-15 2016-06-15
PCT/US2017/037797 WO2017218853A1 (en) 2016-06-15 2017-06-15 Methods and compositions for reducing oxidative stress

Publications (1)

Publication Number Publication Date
MX2018015583A true MX2018015583A (es) 2019-05-16

Family

ID=60663367

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018015583A MX2018015583A (es) 2016-06-15 2017-06-15 Metodos y composiciones para reducir el estres oxidativo.

Country Status (11)

Country Link
US (2) US20190247325A1 (es)
EP (2) EP3471745B1 (es)
JP (1) JP7454332B2 (es)
CN (1) CN109641022A (es)
AU (3) AU2017286659A1 (es)
BR (1) BR112018076282A2 (es)
CA (1) CA3027966A1 (es)
EA (1) EA201990030A1 (es)
IL (1) IL263676B2 (es)
MX (1) MX2018015583A (es)
WO (2) WO2017218853A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2926186T3 (es) 2016-06-28 2022-10-24 Trichomeshell Ltd Una forma de dosificación para vaporización y fumar
US20190314436A1 (en) * 2016-11-04 2019-10-17 Korea Bio Medical Science Institute Co., Ltd Pharmaceutical composition for prevention or treatment of liver cancer and health functional food
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
US20180221333A1 (en) * 2017-03-22 2018-08-09 Rise Research Inc Optimized cannabis-based aphrodisiac and mood enhancer
US11452707B2 (en) * 2017-08-31 2022-09-27 Hanyi Bio-Technology (Beijing) Co., Ltd. Use of cannabidiol in preparation of drugs for resisting against influenza
CA3089994A1 (en) 2018-01-31 2019-08-08 Canopy Holdings, LLC Hemp powder
WO2019159176A1 (en) * 2018-02-18 2019-08-22 Scicann Therapeutics Inc. Compositions and methods for treatment of neurodegenerative diseases
US20190321330A1 (en) * 2018-04-18 2019-10-24 Canopy Growth Corporation Cannabis placebo compositions, delivery vehicles and a method for colour matching/neutralization of cannabis products
CN109142700A (zh) * 2018-07-27 2019-01-04 新乡医学院 一种对小鼠不同器官氧化应激作用的检测方法
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol
BR112021014976A2 (pt) * 2019-02-08 2021-10-05 Schedule 1 Therapeutics, Inc. Composições compreendendo canabinoides e métodos de uso das mesmas
US20220211794A1 (en) * 2019-05-07 2022-07-07 Sadanand Prabhakar SARDESHMUKH Herbo-lipid composition and the process for preparation thereof
US11622956B1 (en) 2019-06-26 2023-04-11 RCR BioPharma Compound and method for treating diseases and disorders
US20210023005A1 (en) * 2019-07-26 2021-01-28 Landsteiner Scientific S.A. De C.V. Cannabinoid-containing compositions in the form of spheres or sphere-like particles, methods for their preparation, and therapeutic applications
EP4021472A4 (en) * 2019-08-29 2023-10-11 Sunstar Joint Stock Company NATURAL ESSENTIAL OIL COMPOSITION FOR RELAXATION OF NERVES, GOOD SLEEP AND PREVENTION OF COLDS AND FLU
AU2020351209A1 (en) * 2019-09-18 2022-05-12 Pharma Cosmetix Research, Llc Endocannabinoid mimetic and anti-inflammatory compound containing compositions, methods of preparation and uses thereof
US11542243B1 (en) 2019-09-26 2023-01-03 FusionFarms, LLC Method of converting delta9-THC to delta10-THC and the purification of the delta10-THC by crystallization
US12343315B2 (en) 2019-10-21 2025-07-01 Avicanna Inc. Topical cannabinoid compositions for clear skin
CA3160612C (en) * 2019-12-04 2024-04-16 West Liberty Foods, L.L.C. Automated food preparation and packaging systems, methods, and apparatus
AU2020403651A1 (en) 2019-12-09 2022-07-07 Nicoventures Trading Limited Oral product comprising a cannabinoid
US20210299203A1 (en) * 2020-03-26 2021-09-30 Johnson & Johnson Consumer Inc. Compositions comprising carum carvi and rosmarinus officinalis extracts and methods of using same
US20230125212A1 (en) * 2020-03-29 2023-04-27 Ami MOLAD Means and methods for enhancing cannabinoids efficacy
WO2021202413A1 (en) * 2020-03-30 2021-10-07 Ojai Energetics Pbc Systems, methods, and compositions for infections
EP4142684A1 (en) 2020-04-29 2023-03-08 Mary Kay, Inc. Cosmetic compositions and methods comprising plumeria alba flower extract
WO2022012551A1 (en) * 2020-07-14 2022-01-20 Natur-Tech Pharmacal Co., Ltd Compositions and uses thereof
KR102474046B1 (ko) * 2020-10-05 2022-12-06 태웅식품 주식회사 숙취해소 및 혈행 개선을 위한 헛개 음료의 제조방법
US11839602B2 (en) 2020-11-25 2023-12-12 Nicoventures Trading Limited Oral cannabinoid product with lipid component
WO2022187123A1 (en) 2021-03-01 2022-09-09 Bidio, Llc Cannabinoid infused coffee and methods of making same
US20230372425A1 (en) * 2021-05-06 2023-11-23 Manuka Therapeutics Ltd. Topical compositions containing manuka oil and palmarosa oil for treating skin conditions
IT202100016433A1 (it) * 2021-06-23 2022-12-23 Nanomnia Srl Metodo per la realizzazione di una micro/nanoemulsione fitosanitaria
EP4408196A4 (en) * 2021-10-01 2025-07-23 Native Ingredients And Health Res Organisation Pty Ltd METHOD OF TREATMENT OF CANCER
BE1030599B1 (fr) * 2022-11-23 2024-01-09 Erck Emmanuelle Van Composition à base d'huiles essentielles pour le traitement et la prévention des maladies inflammatoires des voies aériennes chez les animaux
CN115869221B (zh) * 2022-11-30 2024-09-13 时垠(上海)生物科技有限公司 一种含白松露菌提取物的脂质体及其应用
WO2025054536A1 (en) * 2023-09-07 2025-03-13 The Regents Of The University Of California Cannabinoid delivery
JP7653484B1 (ja) 2023-09-13 2025-03-28 軒郁國際股▲フン▼有限公司 精油組成物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3456049A (en) 1965-05-25 1969-07-15 Ciba Geigy Corp Gradual-release tablet
CA2329626A1 (en) 1998-04-21 1999-10-28 The Government Of The United States Of America As Represented By The Sec Retary, Department Of Health And Human Services Cannabinoids as antioxidants and neuroprotectants
KR100531472B1 (ko) * 2002-08-09 2005-11-28 주식회사 이롬 항산화 활성을 가지는 찔레나무 추출물을 포함하는 화장품 조성물 및 상기 추출물의 제조방법
WO2005071060A2 (en) 2004-01-08 2005-08-04 North Carolina State University Methods and devices for microencapsulation of cells
WO2006009769A1 (en) 2004-06-17 2006-01-26 Forest Laboratories, Inc. Modified release formulation of memantine
EP1827393A4 (en) 2004-12-09 2012-04-18 Insys Therapeutics Inc AT ROOM TEMPERATURE, STABLE DRONABINOL FORMULATIONS
EA013474B1 (ru) 2005-06-16 2010-04-30 Форест Лэборэтериз, Инк. Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина
US8980940B2 (en) * 2006-11-10 2015-03-17 Johnson Matthey Public Limited Company Stable cannabinoid compositions and methods for making and storing them
GB2448535A (en) * 2007-04-19 2008-10-22 Gw Pharma Ltd New use for cannabinoid-containing plant extracts
WO2009107876A1 (ja) * 2008-02-29 2009-09-03 独立行政法人科学技術振興機構 酸化ストレスを測定するためのプローブ試薬
FR2930445B1 (fr) * 2008-04-29 2012-06-08 Am Phyto Conseil Utilisation d'une composition contenant le 7-dehydrocholesterol ou un extrait naturel de micro-organisme ou vegetal ou animal
EP2359698B1 (en) * 2010-01-22 2013-12-04 Symrise AG Compositions with a surfactant system comprising saponins, and lecithin
US20130224281A1 (en) * 2011-04-07 2013-08-29 United States Of America As Represented By The Administrator Of The National Aeronautics & Space Method and composition for ameliorating the effects for a subject exposed to radiation or other sources of oxidative stress
US20140023701A1 (en) * 2011-04-07 2014-01-23 Nugevity Llc Method and Composition for Ameliorating the Effects tor a Subject Exposed to Radiation or Other Sources of Oxidative Stress
WO2013009928A1 (en) * 2011-07-11 2013-01-17 Organic Medical Research Cannabinoid formulations
GB2495118B (en) * 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
US8637461B2 (en) * 2011-12-28 2014-01-28 Kuwait University Method of diagnosing and treating oxidative stress-impaired wound healing
CA2895805A1 (en) * 2012-12-18 2014-06-26 Kotzker Consulting Llc Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
WO2014134281A1 (en) * 2013-02-28 2014-09-04 Full Spectrum Laboratories Limited Biosynthesis of cannabinoids
US9907846B2 (en) * 2013-04-01 2018-03-06 Mx Adjuvac Ab Nanoparticles, composed of sterol and saponin from Quillaja saponaria Molina for use in pharmaceutical compositions
US8828457B1 (en) * 2013-06-28 2014-09-09 Dr Pepper/Seven Up, Inc. Emulsions providing stable vitamin compositions and methods of forming compositions thereof
JP2016537412A (ja) * 2013-10-31 2016-12-01 フル スペクトラム ラボラトリーズ，エルティーディー． テルペン及びカンナビノイドの製剤
US20180235904A1 (en) * 2014-10-08 2018-08-23 Earth Science Tech, Inc. Cannabidiol compositions including mixtures and uses thereof
JP2018505912A (ja) * 2014-12-12 2018-03-01 オーハイ エナジェティクス ピービーシー マイクロカプセル化カンナビノイド組成物
US10542770B2 (en) * 2016-03-18 2020-01-28 Aceso Wellness LLC Cannabinoid emulsion product and process for making the same

Also Published As

Publication number Publication date
EP3471745B1 (en) 2025-03-26
EP3471745A4 (en) 2020-01-22
US20190247325A1 (en) 2019-08-15
IL263676B2 (en) 2025-06-01
EA201990030A1 (ru) 2019-06-28
JP7454332B2 (ja) 2024-03-22
BR112018076282A2 (pt) 2019-03-26
WO2017218845A1 (en) 2017-12-21
EP4585271A3 (en) 2025-10-15
WO2017218853A1 (en) 2017-12-21
JP2019523775A (ja) 2019-08-29
IL263676A (en) 2019-01-31
EP4585271A2 (en) 2025-07-16
IL263676B1 (en) 2025-02-01
AU2025267516A1 (en) 2025-12-11
CA3027966A1 (en) 2017-12-21
US20240082174A1 (en) 2024-03-14
CN109641022A (zh) 2019-04-16
AU2023278131A1 (en) 2024-01-04
AU2017286659A1 (en) 2019-01-17
EP3471745A1 (en) 2019-04-24

Similar Documents

Publication Publication Date Title
MX2018015583A (es) Metodos y composiciones para reducir el estres oxidativo.
CL2019000511A1 (es) Inhibidores de procesos metabólicos celulares.
MX2020009347A (es) Picolinamidas como fungicidas.
CL2018001744A1 (es) Compuestos depsipeptídicos como anthelmínticos
CL2017000410A1 (es) Y-diquetonas para el tratamiento y la prevención de envejecimiento cutáneo y arrugas.
MX2021001566A (es) Compuestos depsipeptidicos como anthelminticos.
ECSP19057403A (es) Usos terapéuticos de un polvo de insectos
CL2017000080A1 (es) Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer
CO2017000552A2 (es) Bifenil amidas con grupos éter modificados como inhibidores de hsp90 e inductores de hsp70
MX395015B (es) Composiciones microencapsuladas de cannabinoides
MX2021006734A (es) Metodo para tratar el cancer.
MX395249B (es) Composiciones antimicrobianas y sus usos.
CR20160446A (es) Compuestos de azolina
MX2015013948A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
CL2017001135A1 (es) Anticuerpos mejorados contra il-6
MX2018005165A (es) Métodos para el tratamiento de padecimientos asociados con la activacion del complemento dependiente de masp-2.
MX2017006167A (es) Compuestos que interactúan con glicanos y métodos de uso.
BR112018009492A2 (pt) combinação de antioxidantes naturais
MX2019015124A (es) Composicion que comprende manosa oligosacarido y proceso para realizarla y uso de esta.
UY35579A (es) Composiciones antiparasitarias de espiro-isoxazolina de acción prolongada
BR112017008481A2 (pt) composto antimicótico
WO2018156448A8 (en) Prediction and treatment of immunotherapeutic toxicity
BR112017022281A2 (pt) métodos para tratar câncer
AR056111A1 (es) Combinaciones sinergicas de imazalilo
CL2017002967A1 (es) Beta-caseinas a2 y capacidad antioxidante.